Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform
This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it has evolved, and some changes that would improve it in the context of the national health reform process. The present paper buil...
| Main Author: | |
|---|---|
| Format: | Policy Note |
| Language: | English en_US |
| Published: |
Washington, DC
2017
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/933311468216270181/Main-report http://hdl.handle.net/10986/27598 |
| id |
okr-10986-27598 |
|---|---|
| recordtype |
oai_dc |
| repository_type |
Digital Repository |
| institution_category |
Foreign Institution |
| institution |
Digital Repositories |
| building |
World Bank Open Knowledge Repository |
| collection |
World Bank |
| language |
English en_US |
| topic |
ACCESS TO PHARMACEUTICALS ACCOUNTABILITY ACCOUNTING ACTIVE INGREDIENTS ADVERTISING AGGRESSIVE AGING ANALGESICS ANESTHESIA ANTIBIOTICS AVERAGE PRICE BENCHMARKS BIDDING BLOOD PRODUCTS BRAND BRAND NAME BRAND NAME DRUGS BRAND NAMES BUDGETING CAPACITY BUILDING CENTER FOR HEALTH CHINESE POPULATION CHRONIC CONDITIONS CHRONIC DISEASES CITIZENS CLINICAL GUIDELINES CLINICAL TRIALS COMMUNITY HEALTH COMMUNITY PHARMACIES COMPETITIVE BIDDING COOPERATIVE MEDICAL INSURANCE CORRUPTION DEVELOPING COUNTRIES DIABETES DIFFERENTIAL PRICING DISSEMINATION DOMESTIC EXPENDITURES DOMESTIC MANUFACTURERS DOMESTIC MARKET DONATIONS DOSAGES DRUG PRESCRIBING DRUG PRICES DRUGS ECONOMIC TRANSITION ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES EXPORT MARKET FAMILIES FAMILY PLANNING FEES FOR SERVICES GENERIC DRUGS GMP GOOD MANUFACTURING PRACTICES HEALTH CARE HEALTH CENTERS HEALTH FACILITIES HEALTH INSURANCE HEALTH POLICY HEALTH REFORM HEALTH SECTOR HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL PHARMACIES HOSPITALS HYPERTENSION ILLNESS IMMUNIZATION IMPORTED DRUGS INFORMATION SYSTEM INSURANCE SCHEMES IRRATIONAL USE LARGE CITIES LOCAL GOVERNMENTS MARKET PRICE MARKET PRICES MARKET SHARE MARKETING MARKETPLACE MEDICAL EDUCATION MEDICAL INSURANCE MEDICAL SERVICES MEDICATION MEDICINE MEDICINES MENTAL HEALTH MINISTRY OF HEALTH MONOPOLIES NATIONAL DEVELOPMENT NATIONAL DRUG NATIONAL ESSENTIAL DRUG LISTS NATIONAL LEVEL NATIONAL POLICY NDP NURSES NUTRITION PACKAGING PATENTS PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL COMPANIES PHARMACEUTICAL COST CONTAINMENT PHARMACEUTICAL COSTS PHARMACEUTICAL DISTRIBUTION PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL LAW PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL PRICES PHARMACEUTICAL PRICING PHARMACEUTICAL PRODUCTS PHARMACEUTICAL QUALITY PHARMACEUTICAL REFORM PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICALS PHARMACOECONOMIC EVALUATION PHARMACY PHYSICIANS POOLED PROCUREMENT POOR FAMILIES PRESCRIPTIONS PREVENTIVE HEALTH CARE PRICE ADJUSTMENTS PRICE CAPS PRICE CHANGES PRICE CONTROL PRICE CONTROLS PRICE INCREASES PRICE LIST PRICE REGULATION PRICE SETTING PRICING POLICIES PRICING POLICY PROCUREMENT PUBLIC DEBATE PUBLIC HEALTH PUBLIC HEALTH SERVICES PUBLIC HEARINGS PUBLIC HOSPITALS PURCHASING QUALITY ASSURANCE QUALITY CONTROL QUALITY OF LIFE REBATES RETAIL RETAIL PRICE RETAIL PRICES RURAL AREAS SALE SALES SCIENTIFIC EVIDENCE SOCIAL CONSEQUENCES SOCIAL HEALTH INSURANCE SOCIAL POLICY SOCIAL SECURITY SOCIAL WELFARE SPECIFIC INCENTIVES STATE PLANNING SUBSTITUTE SUPPLY CHAIN SURGERY SURPLUS TENDERING TRADITIONAL MEDICINES TREATMENT GUIDELINES URBAN AREAS URBAN CENTERS URBAN COMMUNITY VACCINES WHOLESALE PRICE WORKERS WORLD HEALTH ORGANIZATION |
| spellingShingle |
ACCESS TO PHARMACEUTICALS ACCOUNTABILITY ACCOUNTING ACTIVE INGREDIENTS ADVERTISING AGGRESSIVE AGING ANALGESICS ANESTHESIA ANTIBIOTICS AVERAGE PRICE BENCHMARKS BIDDING BLOOD PRODUCTS BRAND BRAND NAME BRAND NAME DRUGS BRAND NAMES BUDGETING CAPACITY BUILDING CENTER FOR HEALTH CHINESE POPULATION CHRONIC CONDITIONS CHRONIC DISEASES CITIZENS CLINICAL GUIDELINES CLINICAL TRIALS COMMUNITY HEALTH COMMUNITY PHARMACIES COMPETITIVE BIDDING COOPERATIVE MEDICAL INSURANCE CORRUPTION DEVELOPING COUNTRIES DIABETES DIFFERENTIAL PRICING DISSEMINATION DOMESTIC EXPENDITURES DOMESTIC MANUFACTURERS DOMESTIC MARKET DONATIONS DOSAGES DRUG PRESCRIBING DRUG PRICES DRUGS ECONOMIC TRANSITION ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES EXPORT MARKET FAMILIES FAMILY PLANNING FEES FOR SERVICES GENERIC DRUGS GMP GOOD MANUFACTURING PRACTICES HEALTH CARE HEALTH CENTERS HEALTH FACILITIES HEALTH INSURANCE HEALTH POLICY HEALTH REFORM HEALTH SECTOR HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL PHARMACIES HOSPITALS HYPERTENSION ILLNESS IMMUNIZATION IMPORTED DRUGS INFORMATION SYSTEM INSURANCE SCHEMES IRRATIONAL USE LARGE CITIES LOCAL GOVERNMENTS MARKET PRICE MARKET PRICES MARKET SHARE MARKETING MARKETPLACE MEDICAL EDUCATION MEDICAL INSURANCE MEDICAL SERVICES MEDICATION MEDICINE MEDICINES MENTAL HEALTH MINISTRY OF HEALTH MONOPOLIES NATIONAL DEVELOPMENT NATIONAL DRUG NATIONAL ESSENTIAL DRUG LISTS NATIONAL LEVEL NATIONAL POLICY NDP NURSES NUTRITION PACKAGING PATENTS PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL COMPANIES PHARMACEUTICAL COST CONTAINMENT PHARMACEUTICAL COSTS PHARMACEUTICAL DISTRIBUTION PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL LAW PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL PRICES PHARMACEUTICAL PRICING PHARMACEUTICAL PRODUCTS PHARMACEUTICAL QUALITY PHARMACEUTICAL REFORM PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICALS PHARMACOECONOMIC EVALUATION PHARMACY PHYSICIANS POOLED PROCUREMENT POOR FAMILIES PRESCRIPTIONS PREVENTIVE HEALTH CARE PRICE ADJUSTMENTS PRICE CAPS PRICE CHANGES PRICE CONTROL PRICE CONTROLS PRICE INCREASES PRICE LIST PRICE REGULATION PRICE SETTING PRICING POLICIES PRICING POLICY PROCUREMENT PUBLIC DEBATE PUBLIC HEALTH PUBLIC HEALTH SERVICES PUBLIC HEARINGS PUBLIC HOSPITALS PURCHASING QUALITY ASSURANCE QUALITY CONTROL QUALITY OF LIFE REBATES RETAIL RETAIL PRICE RETAIL PRICES RURAL AREAS SALE SALES SCIENTIFIC EVIDENCE SOCIAL CONSEQUENCES SOCIAL HEALTH INSURANCE SOCIAL POLICY SOCIAL SECURITY SOCIAL WELFARE SPECIFIC INCENTIVES STATE PLANNING SUBSTITUTE SUPPLY CHAIN SURGERY SURPLUS TENDERING TRADITIONAL MEDICINES TREATMENT GUIDELINES URBAN AREAS URBAN CENTERS URBAN COMMUNITY VACCINES WHOLESALE PRICE WORKERS WORLD HEALTH ORGANIZATION World Bank Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform |
| geographic_facet |
East Asia and Pacific China |
| relation |
China Health Policy Notes;No. 1 |
| description |
This paper examines the financing,
pricing, and utilization of pharmaceuticals in China the
pharmaceutical system as it has evolved, and some changes
that would improve it in the context of the national health
reform process. The present paper builds upon earlier
critical reviews and other papers published in the series
china health policy notes. The paper is divided into four
parts. The first section provides an overview of the Chinese
pharmaceutical market: how the sector has grown;
China's position in the global market; and size,
composition, and trends in the domestic market. The second
section examines the evolution and status of China's
system of essential medicines, an area emphasized in the
government's health reform plan announced in April
2009. It shows how the use of essential medicines has
evolved over the two decades since the idea was formally
adopted, and discusses why practice has fallen far short of
the ideal. The third section looks at the issue that
dominates today's debate: managing high pharmaceutical
costs. It reviews the components of drug pricing,
underscoring the argument that there is considerable scope
for reducing prices. It looks at government attempts to
control drug prices, and suggests why they did not succeed.
Finally, the fourth section suggests measures to re-chart
the path to reform. |
| format |
Policy Note |
| author |
World Bank |
| author_facet |
World Bank |
| author_sort |
World Bank |
| title |
Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform |
| title_short |
Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform |
| title_full |
Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform |
| title_fullStr |
Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform |
| title_full_unstemmed |
Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform |
| title_sort |
financing, pricing, and utilization of pharmaceuticals in china : the road to reform |
| publisher |
Washington, DC |
| publishDate |
2017 |
| url |
http://documents.worldbank.org/curated/en/933311468216270181/Main-report http://hdl.handle.net/10986/27598 |
| _version_ |
1764464969281175552 |
| spelling |
okr-10986-275982021-04-23T14:04:43Z Financing, Pricing, and Utilization of Pharmaceuticals in China : The Road to Reform World Bank ACCESS TO PHARMACEUTICALS ACCOUNTABILITY ACCOUNTING ACTIVE INGREDIENTS ADVERTISING AGGRESSIVE AGING ANALGESICS ANESTHESIA ANTIBIOTICS AVERAGE PRICE BENCHMARKS BIDDING BLOOD PRODUCTS BRAND BRAND NAME BRAND NAME DRUGS BRAND NAMES BUDGETING CAPACITY BUILDING CENTER FOR HEALTH CHINESE POPULATION CHRONIC CONDITIONS CHRONIC DISEASES CITIZENS CLINICAL GUIDELINES CLINICAL TRIALS COMMUNITY HEALTH COMMUNITY PHARMACIES COMPETITIVE BIDDING COOPERATIVE MEDICAL INSURANCE CORRUPTION DEVELOPING COUNTRIES DIABETES DIFFERENTIAL PRICING DISSEMINATION DOMESTIC EXPENDITURES DOMESTIC MANUFACTURERS DOMESTIC MARKET DONATIONS DOSAGES DRUG PRESCRIBING DRUG PRICES DRUGS ECONOMIC TRANSITION ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES EXPORT MARKET FAMILIES FAMILY PLANNING FEES FOR SERVICES GENERIC DRUGS GMP GOOD MANUFACTURING PRACTICES HEALTH CARE HEALTH CENTERS HEALTH FACILITIES HEALTH INSURANCE HEALTH POLICY HEALTH REFORM HEALTH SECTOR HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL PHARMACIES HOSPITALS HYPERTENSION ILLNESS IMMUNIZATION IMPORTED DRUGS INFORMATION SYSTEM INSURANCE SCHEMES IRRATIONAL USE LARGE CITIES LOCAL GOVERNMENTS MARKET PRICE MARKET PRICES MARKET SHARE MARKETING MARKETPLACE MEDICAL EDUCATION MEDICAL INSURANCE MEDICAL SERVICES MEDICATION MEDICINE MEDICINES MENTAL HEALTH MINISTRY OF HEALTH MONOPOLIES NATIONAL DEVELOPMENT NATIONAL DRUG NATIONAL ESSENTIAL DRUG LISTS NATIONAL LEVEL NATIONAL POLICY NDP NURSES NUTRITION PACKAGING PATENTS PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL COMPANIES PHARMACEUTICAL COST CONTAINMENT PHARMACEUTICAL COSTS PHARMACEUTICAL DISTRIBUTION PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL LAW PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL PRICES PHARMACEUTICAL PRICING PHARMACEUTICAL PRODUCTS PHARMACEUTICAL QUALITY PHARMACEUTICAL REFORM PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICALS PHARMACOECONOMIC EVALUATION PHARMACY PHYSICIANS POOLED PROCUREMENT POOR FAMILIES PRESCRIPTIONS PREVENTIVE HEALTH CARE PRICE ADJUSTMENTS PRICE CAPS PRICE CHANGES PRICE CONTROL PRICE CONTROLS PRICE INCREASES PRICE LIST PRICE REGULATION PRICE SETTING PRICING POLICIES PRICING POLICY PROCUREMENT PUBLIC DEBATE PUBLIC HEALTH PUBLIC HEALTH SERVICES PUBLIC HEARINGS PUBLIC HOSPITALS PURCHASING QUALITY ASSURANCE QUALITY CONTROL QUALITY OF LIFE REBATES RETAIL RETAIL PRICE RETAIL PRICES RURAL AREAS SALE SALES SCIENTIFIC EVIDENCE SOCIAL CONSEQUENCES SOCIAL HEALTH INSURANCE SOCIAL POLICY SOCIAL SECURITY SOCIAL WELFARE SPECIFIC INCENTIVES STATE PLANNING SUBSTITUTE SUPPLY CHAIN SURGERY SURPLUS TENDERING TRADITIONAL MEDICINES TREATMENT GUIDELINES URBAN AREAS URBAN CENTERS URBAN COMMUNITY VACCINES WHOLESALE PRICE WORKERS WORLD HEALTH ORGANIZATION This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it has evolved, and some changes that would improve it in the context of the national health reform process. The present paper builds upon earlier critical reviews and other papers published in the series china health policy notes. The paper is divided into four parts. The first section provides an overview of the Chinese pharmaceutical market: how the sector has grown; China's position in the global market; and size, composition, and trends in the domestic market. The second section examines the evolution and status of China's system of essential medicines, an area emphasized in the government's health reform plan announced in April 2009. It shows how the use of essential medicines has evolved over the two decades since the idea was formally adopted, and discusses why practice has fallen far short of the ideal. The third section looks at the issue that dominates today's debate: managing high pharmaceutical costs. It reviews the components of drug pricing, underscoring the argument that there is considerable scope for reducing prices. It looks at government attempts to control drug prices, and suggests why they did not succeed. Finally, the fourth section suggests measures to re-chart the path to reform. 2017-07-17T19:54:45Z 2017-07-17T19:54:45Z 2010 Policy Note http://documents.worldbank.org/curated/en/933311468216270181/Main-report http://hdl.handle.net/10986/27598 English en_US China Health Policy Notes;No. 1 CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo World Bank Washington, DC Economic & Sector Work :: Policy Note Economic & Sector Work East Asia and Pacific China |